Vienna is in the centre of Europe – ideal for building bridges between East and West, North and South. The EuroMeeting 2014 will be the meeting point and melting pot for all involved in making available the health products of the future.
BASEL, SWITZERLAND (PRWEB) January 07, 2014
More than 3,000 professionals from around the world will gather in Vienna to share knowledge and expertise at DIA’s largest conference in Europe – the EuroMeeting 2014.
The 26th annual EuroMeeting, coming to Austria’s capital from 25-27 March, will provide an interactive forum for representatives from the biopharmaceutical industry, contract research and service organisations, academic research centres, regulatory agencies, health ministries, and patient organisations to discuss pressing issues.
Attendees will have access to more than 100 sessions in 16 parallel themes and the chance to hear from 350+ expert speakers, including representatives from the European Medicines Agency (EMA), the European Commission, the Food and Drug Administration (FDA), and regulatory agencies from around the world. Participants can also find out about the latest innovations in their field by touring the exhibition hall featuring 170 companies, and view the latest research on display through student and professional posters.
EuroMeeting 2014 Co-chair Angelika Joos, Head of Regulatory Policy for EU and Most of World at Merck Sharp and Dohme in Belgium, said: “Vienna is in the centre of Europe – ideal for building bridges between East and West, North and South. The EuroMeeting 2014 will be the meeting point and melting pot for all involved in making available the health products of the future.”
The conference will facilitate debate on key issues in the life sciences industry, from how to involve and inform patients and citizens in the whole lifecycle of health products, to the opportunities and challenges of bringing personalised medicines to market. Other hot topics for discussion include the proposal for the Clinical Trials Directive, initiatives on the Health Technology Assessment (HTA), the start of implementation of the Directive of Falsified Medicines, and how the ‘Horizon 2020’ research programme will contribute to innovation and the availability of medicines and treatments.
Christa Wirthumer-Hoche, Head of the Austrian Medicines and Medical Devices Agency (AGES) and EuroMeeting 2014 Co-chair, said: “This is the event of the year and I would recommend that all professionals working in the regulatory affairs arena come to the EuroMeeting 2014 and listen to the exciting presentations from experts in Europe and worldwide.”
To register to attend, or for more information, visit the EuroMeeting 2014 website at http://www.diahome.org/EM2014. Register by February 11 and save with an early-bird discount.
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Washington, DC; Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. http://www.diahome.org